FDA To Companion Dx Developers: Pre-Trial Assay Validation Is Key
This article was originally published in The Gray Sheet
Executive Summary
Companion diagnostic device makers should ensure their test is analytically validated prior to its use in a drug pivotal trial, FDA stressed at a Sept. 26 meeting at the University of Virginia in Charlottesville.
You may also be interested in...
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.